Live data · NADAC + Part D CY24 · reviewed daily

Insulin Lispro-Aabc (LYUMJEV)

Insulin Analog class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2020-06-15
Generic availableNo (brand-only)
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$139.8M in CY2024 Part D spend154K claims · 56K beneficiaries · 329 plans surveyed

Lowest NADAC
$7.87/unit
4 NDCs benchmarked, lowest of all strengths.
Average NADAC
$12.11
Across all dosage forms in distribution.
Highest NADAC
$20.28
Range is tight.
Plans with PA
33 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Insulin Lispro-Aabc used for?

Insulin Lispro-Aabc is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Insulin Lispro-Aabc?

No. Insulin Lispro-Aabc is brand-only with no generic equivalents currently in market.

How much does my plan pay for Insulin Lispro-Aabc?

Across 329 Part D plans, Insulin Lispro-Aabc averages $12.11/unit (NADAC). Lowest available: $7.87/unit. Highest in distribution: $20.28/unit.

Is Insulin Lispro-Aabc on the FDA shortage list?

Insulin Lispro-Aabc has been discontinued by its manufacturer(s).

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.